Role of GQ signaling for PTH1R-dependent bone growth - skeletal growth is driven by coordinated proliferation and subsequent maturation of chondrocytes within the growth plates of long bones

Active Grant Awarded

Award ID
R21AR088883
Recipient
Awarding agency
Obligated
$200,256

Award facts

Completion date 8% complete
Place of performance
Boston, MA 02114, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services' National Institutes of Health, through the National Institute of Arthritis and Musculoskeletal and Skin Diseases, awarded The General Hospital Corporation, doing business as Massachusetts General Hospital, a grant obligating $200,256 on September 23, 2026, under Assistance Listing 93.846, Arthritis, Musculoskeletal and Skin Diseases Research. Grant R21AR088883 funds research into the role of Gq signaling in parathyroid hormone receptor type 1 (PTH1R)-dependent bone growth. The project tests the hypothesis that altered G protein selectivity, possibly combined with impaired Gas signaling, contributes to growth plate effects of PTH1R helix 8 mutations (E465K and E469K), which cause brachydactyly type E and short stature. It builds on prior work in knock-in mice carrying the human E469K-PTH1R allele and in transfected HEK293 cells showing impaired cAMP generation by both helix 8 mutants. The period of performance runs from the September 23, 2026 award date to August 31, 2028, with work performed in Boston, Massachusetts 02114. The parent program supports research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases.

Description

By mediating the actions of parathyroid hormone-related peptide (PTHRP) in growth plate cartilage, the parathyroid hormone receptor type 1 (PTH1R) plays a central role in these processes. Under physiological conditions, PTH1R-dependent actions primarily involve coupling to the stimulatory G protein (GΑS), leading to activation of camp/PKA signaling that promotes chondrocyte proliferation and delays hypertrophic maturation in growth plates. In addition to GΑS, PTH1R can also engage GΑQ/11 to activate IP3/PKC signaling. Although this pathway has been proposed to promote chondrocyte differentiation and bone mineralization, its functional relevance for skeletal development remains poorly defined. Rare genetic disorders affecting PTH1R signaling have provided important insights into growth plate biology. To extend these investigations, we recently showed that heterozygous mutations in helix 8 (H8) of PTH1R (E465K and E469K) cause brachydactyly type E (BDE) and short stature. This phenotype was recapitulated in our mice expressing the human E469K-PTH1R knock-in allele under the control of the endogenous PTH1R promoter. In vitro studies using transfected HEK293 cells indicate that both H8 mutants show impaired camp generation. Notably, BDE has not been observed with heterozygous PTH1R loss-of-function mutations, which are associated only with dental abnormalities. This suggests that H8 mutations affect chondrocyte biology through a mechanism distinct from PTH1R haploinsufficiency. Remarkably, preliminary data indicate that the E465K mutation shifts PTH1R signaling from GΑS toward GΑQ/11, a pathway previously proposed to accelerate chondrocyte maturation. We therefore hypothesise that altered G protein selectivity contributes - possibly together with impaired GΑS signaling - to the growth plate phenotype in BDE. To test this hypothesis, E465K-PTH1R mice will be generated and crossed with floxed GΑQ/GΑ11-null mice to genetically ablate these two signaling proteins in proliferating growth plate chondrocytes through the COL2 promoter. This experiment will determine the extent to which aberrant IP3/PKC signaling drives skeletal abnormalities thereby defining the balance between GΑS versus GΑQ/11 signaling during skeletal development. We will furthermore test whether pharmacological PTH1R modulators can "tune" G protein selectivity at wild-type and mutant receptors, and whether such modulation improves skeletal outcomes in mice carrying either H8-PTH1R mutation by enhancing GΑS coupling and/or suppressing GΑQ/11 coupling. Together, these studies will define the underexplored interplay between GΑS and GΑQ/11 signaling in skeletal growth, thus providing mechanistic insights into how balanced G protein signaling governs growth plate development. Based on these experiments, new therapeutic strategies may emerge for disorders of impaired longitudinal bone growth. More broadly, our work will advance the understanding of how gpcrs achieve G protein selectivity.

Quick answers

Who received award R21AR088883?

R21AR088883 was awarded to The General Hospital Corporation by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 23, 2026.

How much is award R21AR088883 worth?

$200,256 has been obligated on R21AR088883.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award